Th e fi rst reports of the generation of human induced pluripotent stem cells (hiPSCs) from fi broblasts [1, 2] were greeted with great enthusiasm over their ability to mimic the properties and function of embryonic stem cells without entailing the ethical controversies and resourcing issues associated with the use of human blastocysts in derivation. In the several years since those fi rst reports, new advances in the derivation of hiPSCs from various tissue sources (including those from human patients) and using diverse reprogramming techniques, and in their use as a pluripotent cell source in the induced diff erentiation of a wide array of somatic cell types, have appeared with almost startling rapidity. At least one biotech company (iPierian) has been founded to exploit the commercial potential of these reprogramming technologies, and the Japanese government has established an entire research institute dedicated to fundamental and applied iPSC research (Center for iPS Cell Research and Application, Kyoto University). Clearly, the early expectations surrounding iPSCs have been extraordinary.
A number of recent articles, however, have reported that hiPSCs are, in fact, notably distinct from human embryonic stem cells in terms of their gene expression, epigenetic profi le, proliferative capacity and the susceptibility of their diff erentiated progeny to cellular senescence and apoptosis [3] [4] [5] [6] . Additionally, the head of a prominent human embryonic stem cells fi rm (Geron) has publicly questioned the viability of commercialized therapeutic applications of autologous hiPSCs due to the regulatory requirements imposed by the US Food and Drug Administration [7] . Th e important question now is whether these barriers are high enough to preclude the translation of fundamental hiPSC discoveries into cellular therapies.
As for any innovation with potential medical applications, hiPSCs must satisfy a great number of criteria prior to their introduction into clinical practice. First and foremost come issues of safety and effi cacy. Th e earliest methods for the induction of iPSCs relied on the use of viral vectors, which are encumbered by risks of insertional mutagenesis and transgene reactivation. Numerous alternative methods for inducing pluripotency without the use of gene insertion have been reported, and although their effi ciency remains problematic, if the current rate of progress in methodology continues, these should make it possible to bypass some of the primary safety concerns. But others will still remain, such as the long-term karyotypic stability, appropriate in situ localiza tion, and potential for wayward diff erentiation of somatic cells derived from hiPSCs. Several excellent overviews of the scientifi c challenges confronting cell therapy have described these issues in detail [8] [9] [10] [11] .
Of course, safety alone does not guarantee effi cacy. Despite promising results from animal studies, the viability of the cell transplantation paradigm in human has been demonstrated in only a few contexts, mainly involving the use of hematopoietic stem cell transplants,
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autologous skin and cartilage grafts, or the autologous recellularization of decellularized or engineered tissue. For hiPSCs, or any stem cells used as a source of human somatic cells, to be therapeutically eff ective in transplantation it needs to be shown that their progeny will function normally in the intended site for signifi cant periods of time, which will require extensive testing fi rst in animals, and then in appropriately designed (ideally in randomized, double-masked, multi-site) clinical trials.
Such trials are inevitably costly, and the traditional strategy for drug development suggests one means of undertaking these development expenses is for wellfunded companies to lead the way, motivated by the potential return on investment to be gained from a successful proprietary therapy. However, with few exceptions, the stem cell and regenerative medicine industry has remained inadequately capitalized to carry out large-scale clinical trials independently, and major pharmaceutical fi rms have tended to show more interest in the use of hiPSCs as a source of large, pure populations of specifi c somatic cells for use in drug compound screening and toxicology tests, than they have in therapeutic uses of stem cells and their derivatives.
Th is reluctance is due in part to the great many unanswered questions over the viability of cell therapy business models. At the production stage, issues of endproduct standardization and purity, scalability, and timeliness have yet to be worked out. Similarly, delivery systems for ensuring integration of hiPSC-derived cellular populations must be developed and tested. Even beyond these technical issues lie a host of purely business concerns, including intellectual property, cost-eff ectiveness, and regulatory aff airs. Interested readers are directed to comprehensive reviews of cell medicine business models [12, 13] .
Despite these many hurdles and the newness of the technology, there are already some glimmers of hope for clinical applications of hiPSCs. Diseases of the retina may off er an early test bed for hiPSC-derived cells, in the form of retinal pigmented epithelium, given the relative isolation of the tissue, and the small number of cells required [14] . A second intriguing possibility would be the use of hiPSCs to produce functional cells for use in extra-corporeal applications, such as mature hepatocytes for use in bio-artifi cial livers. If such early applications prove successful, it may help to allay concerns over safety and increase public and regulatory acceptance of the clinical use of hiPSCs, enabling them to establish a solid footing before attempts are made at treating more complex and deeply rooted disorders.
At the same time, it will be important for cell therapy pioneers to investigate alternative routes for funding their work, so as to ensure the standards of safety and effi cacy expected of small molecules are also met by cellular applications. In countries with socialized healthcare, governments have a strong interest in obtaining access to low-cost and eff ective long-term remedies, and may prove willing to invest in research and development if the economics of the cell therapy strategy are shown to be attractive. Japan has taken some steps in this direction, both in establishing the fi rst centre dedicated entirely to hiPSC research, with an emphasis on application, and by publishing a draft of what looks to be the world's fi rst governmental regulations specifi cally focused on hiPSC-derived cell safety and quality [15] .
As can be seen, a great many issues must be resolved before hiPSCs can be responsibly introduced to the clinic. But it is important to stress that such hurdles have confronted other fl edgling technologies that subsequently revolutionized medicine as well. None of the diffi culties confronting hiPSCs appears to be inherently insurmountable, and given the revolutionary advances that successful applications of reprogramming and cell transplantation might one day bring, it would seem that, for now, the sustained investment of suffi cient eff ort, capital and time remain imperative.
Abbreviations hiPSC, human induced pluripotent stem cell.
